Jul 19, 2022
As Helena and Marc wrap up this season, they’re joined by Mike Watson, Chief Executive Officer of Mevox – a company committed to bringing vaccine technology into the 21st century.
Mike discusses the importance of developing new measles, mumps and rubella (MMR) vaccines, Mevox’s success so far in achieving this ambition – reaching series B funding – and its future trajectory, how COVID-19 will impact the future of vaccine development, along with a whole host of other fascinating insights. As Helena’s favourite interview of Season 2, it’s not one to be missed!
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The return of the vaccines https://www.emg-gold.com/post/the-return-of-the-vaccines
Routine vaccinations: road to recovery https://www.emg-gold.com/post/routine-vaccinations-road-to-recovery
A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna
Moderna set to bring mRNA innovation to UK https://www.emg-gold.com/post/moderna-set-to-bring-mrna-innovation-to-uk
GSK warns against vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency